19,029 results match your criteria Aplastic Anemia


Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.

Int J Clin Oncol 2019 Mar 14. Epub 2019 Mar 14.

Division of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan.

Background: Radium-223 is a first-in-class targeted alpha therapy to prolong overall survival (OS) in castration-resistant prostate cancer with bone metastases (mCRPC). The aim of the present analysis was to assess the long-term safety with radium-223 in Japanese patients with mCRPC.

Methods: Patients with symptomatic mCRPC, ≥ 2 bone metastases and no known visceral metastases received up to 6 injections of radium-223 (55 kBq/kg), one every 4 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-01389-4DOI Listing
March 2019
1 Read

Eltrombopag induces major non-toxic hypersiderraemia.

Br J Haematol 2019 Mar 15. Epub 2019 Mar 15.

Department of Biochemistry, Nantes University Hospital, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15863DOI Listing

Treatment of myelodysplastic syndrome in the era of next-generation sequencing.

J Intern Med 2019 Mar 14. Epub 2019 Mar 14.

Department of Clinical Science, University of Bergen, Bergen, Norway.

Next-generation sequencing (NGS) is rapidly changing the clinical care of patients with myelodysplastic syndrome (MDS). NGS can be used for various applications: (i) in the diagnostic process to discriminate between MDS and other diseases such as aplastic anaemia, myeloproliferative disorders and idiopathic cytopenias; (ii) for classification, for example, where the presence of SF3B1 mutation is one criterion for the ring sideroblast anaemia subgroups in the World Health Organization 2016 classification; (iii) for identification of patients suitable for targeted therapy (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/joim.12893DOI Listing
March 2019
1 Read

Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study.

Ann Hematol 2019 Mar 13. Epub 2019 Mar 13.

CEINGE Biotecnologie Avanzate, Naples, Italy.

In this study, we aimed at disclosing the main features of paroxysmal nocturnal hemoglobinuria (PNH) clones, their association with presentation syndromes, and their changes during follow-up. A large-scale, cooperative collection (583 clones from 529 patients) of flow cytometric and clinical data was entered into a national repository. Reason for testing guidelines were provided to the 41 participating laboratories, which followed the 2010 technical recommendations for PNH testing by Borowitz. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03644-8DOI Listing
March 2019
1 Read

Current concepts of the Pathogenesis of Aplastic Anemia.

Curr Pharm Des 2019 Mar 12. Epub 2019 Mar 12.

Department of Hematology Tianjin Medical University General Hospital 154 Anshan St, Heping District, Tianjin. China.

Abnormal activation of the immune system plays an important role in the pathogenesis of aplastic anemia (AA). Various immune cells and cytokines constitute a complex immune network, leading to bone marrow failure. The known pathogenesis is an increase of the myeloid dendritic cell (mDC)/ plasmacytoid dendritic cell (pDC) ratio, which causes the ratio of T helper (Th)1/Th2 to be skewed in favor of Th1 and eventually leads to an abnormal activation of cytotoxic T lymphocyte (CTL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612825666190313113601DOI Listing
March 2019
1 Read

The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.

Cell Stem Cell 2019 Mar;24(3):405-418.e7

Laboratory of Regenerative Hematopoiesis, Swiss Institute for Experimental Cancer Research (ISREC) & Institute of Bioengineering (IBI), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland; Service and Central Laboratory of Hematology, Departments of Oncology and of Laboratories, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address:

It has been recently shown that increased oxidative phosphorylation, as reflected by increased mitochondrial activity, together with impairment of the mitochondrial stress response, can severely compromise hematopoietic stem cell (HSC) regeneration. Here we show that the NAD-boosting agent nicotinamide riboside (NR) reduces mitochondrial activity within HSCs through increased mitochondrial clearance, leading to increased asymmetric HSC divisions. NR dietary supplementation results in a significantly enlarged pool of progenitors, without concurrent HSC exhaustion, improves survival by 80%, and accelerates blood recovery after murine lethal irradiation and limiting-HSC transplantation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19345909193006
Publisher Site
http://dx.doi.org/10.1016/j.stem.2019.02.012DOI Listing
March 2019
6 Reads

Aplastic anaemia preceding acute lymphoblastic leukaemia in an adult with FAT1 mutation.

Minerva Med 2019 Mar 4. Epub 2019 Mar 4.

Department of Hematopathology, Jining NO.1 People's Hospital, Jining, Shandong, China -

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0026-4806.19.06013-0DOI Listing
March 2019
1 Read

[Progressive multifocal leukoencephalopathy developing subsequent to cord blood transplantation in a patient with severe aplastic anemia].

Rinsho Ketsueki 2019 ;60(2):93-98

Department of Neurology, Mishuku Hospital.

A 68-year-old female with severe aplastic anemia (SAA) refractory to initial immunosuppressive therapy, including anti-thymocyte globulin (ATG) and cyclosporine, received a reduced-intensity cord blood transplant (CBT) in June 2015. Tacrolimus (TAC) and mycophenolate mofetil were administered for graft-versus-host disease (GVHD) prophylaxis, and she received prolonged TAC and prednisolone to treat chronic GVHD. The patient presented with progressive ataxia 14 months after CBT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.60.93DOI Listing
January 2019
2 Reads

Hematologic Complications of Immune Checkpoint Inhibitors.

Oncologist 2019 Feb 28. Epub 2019 Feb 28.

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Immune checkpoint inhibitors have improved outcomes for patients with numerous hematological and solid cancers. Hematologic toxicities have been described, but the spectrum, timing, and clinical presentation of these complications are not well understood. We used the World Health Organization's pharmacovigilance database of individual-case-safety-reports (ICSRs) of adverse drug reactions, VigiBase, to identify cases of hematologic toxicities complicating immune checkpoint inhibitor therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0574DOI Listing
February 2019
1 Read

Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes.

Vox Sang 2019 Feb 28. Epub 2019 Feb 28.

Department of Vigilance, Haemovigilance, Site de Lyon Décines, Etablissement français du Sang Auvergne Rhône-Alpes, Décines-Charpieu Cedex, France.

Background And Objectives: Patients with aplastic anaemia or myelodysplastic syndromes frequently receive transfusions in an attempt to correct anaemia and/or thrombocytopenia, putting them at risk of adverse transfusion reactions. The aim of this study is to evaluate the incidence and the types of adverse transfusion reactions in these patients.

Materials And Methods: Adverse transfusion reaction reported in transfused patients with aplastic anaemia or myelodysplastic syndromes from all the hospitals in the Auvergne-Rhône-Alpes region of France were extracted from the national haemovigilance database system and analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vox.12765DOI Listing
February 2019
3 Reads

Multiple risks analysis for aplastic anemia in Zhejiang, China: A case-control study.

Medicine (Baltimore) 2019 Feb;98(8):e14519

Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University.

To understand the risks associated with aplastic anemia (AA) in 4 cities of Zhejiang Province, China, with special focus on the joint contributions of multiple risks.Based on an Electronic Data Capture (EDC), a case control study was carried out. Data regarding socio-demographic, diseases history, living habits, and exposures to toxic substances, etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014519DOI Listing
February 2019
4 Reads

Risk Factors and Predictive Scoring System for Post-Transplantation Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Feb 20. Epub 2019 Feb 20.

Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan. Electronic address:

We analyzed data from 64,539 consecutive patients in the Japanese national transplant registry, including 40,195 allogeneic hematopoietic stem cell transplantation (HSCT) recipients, 24,215 autologous HSCT recipients, and 129 syngeneic HSCT recipients, of whom 299 developed Epstein-Barr virus-positive post-transplantation lymphoproliferative disorder (PTLD). The probability of developing PTLD at 2years post-HSCT was .79% after allogeneic transplantation, . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.016DOI Listing
February 2019
1 Read

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma.

Case Rep Oncol 2019 Jan-Apr;12(1):29-32. Epub 2019 Jan 4.

Department of Oncology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.

Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495980DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381922PMC
January 2019
1 Read

A Mosquito Bite with Devastating Complications in an Immunocompromised Patient.

Case Rep Oncol 2019 Jan-Apr;12(1):22-28. Epub 2019 Jan 4.

Klinik für Innere Medizin II, Hämatologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.

Infectious complications such as invasive aspergillosis or infection with (SM) in immunocompromised patients are associated with a high mortality rate. Our report concerns a 40-year-old male newly diagnosed very severe aplastic anemia (vSAA) who in consequence of a mosquito bite was suffering from skin lesion and consecutive soft tissue phlegmon subsequent to the administration of antithymocyte globulin; a full-thickness autologous meshed skin graft successfully performed to cover skin ulcera after allogeneic stem cell transplantation (SCT). This unusual case illustrates the importance of appropriate diagnosis, anti-infective therapy and close interdisciplinary diagnostic algorithms to minimalize side effects and the selection of resistant strains and to improve patients' outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495878DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381905PMC
January 2019

CD56 natural killer cells exhibit abnormal phenotype and function in severe aplastic anemia.

Int J Lab Hematol 2019 Feb 19. Epub 2019 Feb 19.

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.

Introduction: CD56 NK cells have been highlighted to serve immunoregulatory functions. However, their roles in severe aplastic anemia (SAA) have not been elucidated.

Methods: Here, we investigated the quantities, phenotypes, cytokine secretion abilities, and the cytotoxicities of peripheral CD56 NK cells along with CD56 NK cells obtained from patients with SAA, SAA in remission (R-SAA), and healthy controls (HC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.12982DOI Listing
February 2019
1 Read

F-FLT PET/MRI for bone marrow failure syndrome-initial experience.

EJNMMI Res 2019 Feb 15;9(1):16. Epub 2019 Feb 15.

Biomedical Imaging Research Center, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji-cho, Fukui, 910-1193, Japan.

Background: Bone marrow failure syndrome (BMFS) is a heterogeneous group of disorders associated with single- or multiple-lineage cytopenia and failure of normal hematopoiesis. We assessed the feasibility of integrated PET/MRI with 3'-deoxy-3'-F-fluorothymidine (F-FLT) to assess the pathophysiology of whole-body bone marrow for the diagnosis and monitoring of BMFS. Twenty-five consecutive patients with BMFS underwent a pre-treatment F-FLT PET/MRI scan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-019-0490-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377687PMC
February 2019
2 Reads

Corticosteroid Therapy for Indeterminate Pediatric Acute Liver Failure and Aplastic Anemia with Acute Hepatitis.

J Pediatr 2019 Feb 12. Epub 2019 Feb 12.

Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL.

Objective: To examine the characteristics and outcomes of a multicenter patient cohort with indeterminate pediatric acute liver failure (IND-PALF) and with aplastic anemia with acute hepatitis treated with corticosteroids.

Study Design: Retrospective study of patients age 1-17 years with IND-PALF and aplastic anemia with acute hepatitis who presented between 2009 and 2018 to 1 of 4 institutions and were treated with corticosteroids for presumed immune dysregulation.

Results: Of 28 patients with IND-PALF (median of 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpeds.2018.12.042DOI Listing
February 2019
1 Read

Contribution of autophagy-related gene 5 variants to acquired aplastic anemia in Han-Chinese population.

J Cell Biochem 2019 Feb 14. Epub 2019 Feb 14.

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, P. R. China.

Immune-mediated quantitative and qualitative defects of hematopoietic stem/progenitor cells (HSPCs) play a vital role in the pathophysiology of acquired aplastic anemia (AA). Autophagy is closely related to T cell pathophysiology and the destiny of HSPCs, in which autophagy-related gene 5 (ATG5) is indispensably involved. We hypothesized that genetic variants of ATG5 might contribute to AA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.28418DOI Listing
February 2019

Thymic neoplasms patients complicated with bronchiectasis: Case series in a Chinese hospital and literature review.

Thorac Cancer 2019 Feb 13. Epub 2019 Feb 13.

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: Bronchiectasis is a rare complication in patients with thymic neoplasm. The aim of this study was to investigate the clinical and radiological manifestations, laboratory tests, pathologic features, and outcome of treatment of bronchiectasis in patients with thymic neoplasm.

Methods: From January 2000 to January 2018, 20 patients with a diagnosis of thymic neoplasm and bronchiectasis were hospitalized at the Peking Union Medical College Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13000DOI Listing
February 2019
4 Reads
1.126 Impact Factor

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.

Bone Marrow Transplant 2019 Feb 6. Epub 2019 Feb 6.

Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.

Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0465-9DOI Listing
February 2019
1 Read

GDF11 is increased in patients with aplastic anemia.

Hematology 2019 Dec;24(1):331-336

a Department of Hematology, General Hospital , Tianjin Medical University , Tianjin , People's Republic of China.

Object: To explore the critical role of growth differentiation factor 11 (GDF11) in the pathobiology of aplastic anemia (AA).

Methods: We have examined the serum GDF11 levels for 79 AA patients and 30 healthy controls. A total of 79 AA patients, which included 29 new diagnosed (untreated) cases, 14 cases with no response, 21 partial remission (PR) cases and 15 complete remission (CR) cases after immunosuppressive therapy (IST). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/16078454.2019.1
Publisher Site
http://dx.doi.org/10.1080/16078454.2019.1574386DOI Listing
December 2019
5 Reads

A Case of Aplastic Anemia Associated With Long-Term Metronidazole Use.

J Pharm Pract 2019 Feb 6:897190019825584. Epub 2019 Feb 6.

4 Division of Blood and Marrow Transplantation, Department of Medicine, UC San Diego Health, La Jolla, CA, USA.

Metronidazole is a nitroimidazole antibacterial agent that is highly effective for the treatment of protozoal and anaerobic infections. Metronidazole is known to cause hematologic adverse effects, including a reversible mild neutropenia; in rare circumstances, thrombocytopenia has been associated with metronidazole treatment. We present a case of aplastic anemia related to the extended use of metronidazole. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0897190019825584DOI Listing
February 2019
7 Reads

[Evolution of aplastic anemia in a patient on chronic hemodialysis. Sixteen years later…].

Authors:
Jorge Vega Stieb

Rev Med Chil 2018 Sep;146(9):1085

Departamento de Medicina, Escuela de Medicina, Universidad de Valparaíso, Chile.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/s0034-98872018000901085DOI Listing
September 2018

Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.

Biol Blood Marrow Transplant 2019 Feb 1. Epub 2019 Feb 1.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington. Electronic address:

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic cell disease characterized by the destruction of hematopoietic cells through activation of the complement system with manifestations that can be life-threatening including hemolysis, thrombosis, and marrow failure. Allogeneic hematopoietic cell transplantation (HCT) remains the sole cure for PNH, but eculizumab, a terminal complement inhibitor of C5, has been used to prevent complement-mediated hemolysis in patients with PNH since its approval by the Food and Drug Administration in 2007. We examined outcomes of HCT in patients with PNH to evaluate the effects of disease subtype, conditioning intensity, and eculizumab use either pre-HCT or post-HCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.033DOI Listing
February 2019
2 Reads

Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 30. Epub 2019 Jan 30.

Blood and Marrow Transplant Center, Florida Hospital Cancer Institute, Orlando, Florida. Electronic address:

Thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-SCT) can pose significant problems in management of patients. Eltrombopag is a small-molecule thrombopoietin receptor agonist that has been approved for use in immune thrombocytopenic purpura and aplastic anemia; but its use after allo-SCT is limited. Between 2014 and 2017, we treated 13 patients with eltrombopag for poor platelet engraftment without evidence of relapse at the time of initiation, including 6 patients with primary platelet engraftment failure and 7 with secondary platelet engraftment failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.027DOI Listing
January 2019
2 Reads
3.404 Impact Factor

Reprogramming of bone marrow derived mesenchymal stromal cells to human induced pluripotent stem cells from pediatric patients with hematological diseases using a commercial mRNA kit.

Blood Cells Mol Dis 2019 May 24;76:32-39. Epub 2019 Jan 24.

Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens 11527, Greece.

The potential use of patient-specific induced pluripotent stem cells (hiPSCs) in the study and treatment of hematological diseases requires the setup of efficient and safe protocols for hiPSC generation. We aimed to adopt a reprogramming method for large-scale production of integration-free patient-specific hiPSC-lines in our stem cell processing laboratory, which supports a pediatric hematopoietic stem cell transplant unit located at a tertiary care children's hospital. We describe our 5-year experience in generation of hiPSC-lines from human bone marrow-derived mesenchymal stromal cells (BM-MSCs) using synthetic mRNAs encoding reprogramming factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcmd.2019.01.003DOI Listing
May 2019
1 Read

Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.

Biol Blood Marrow Transplant 2019 Jan 29. Epub 2019 Jan 29.

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, California.

Paroxysmal nocturnal hemoglobinuria (PNH) is frequently seen in the context of other aplastic anemia and myelodysplastic syndromes and is associated with hemolysis and increased thromboembolic events. Allogeneic hematopoietic stem cell transplantation (alloHCT) is the sole curative treatment but is associated with significant morbidity. The terminal complement inhibitor eculizumab reduces hemolysis and thromboembolic events and is the sole Food and Drug Administration-approved therapy for PNH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.025DOI Listing
January 2019
3 Reads

False Negativity of Tc-99m Labeled Sodium Phytate Bone Marrow Imaging Under the Effect of G-CSF Prescription in Aplastic Anemia: A Case Report.

Asia Ocean J Nucl Med Biol 2019 ;7(1):84-88

Department of Radiology and Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic cytokine which controls the differentiation and growth of hematopoietic cells in the bone marrow. We report a severe aplastic anemia (SAA) patient with false-negative Tc sodium phytate bone marrow imaging findings under concurrent G-CSF therapy. The first bone marrow imaging showed a normal bone marrow activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22038/AOJNMB.2018.11804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352050PMC
January 2019
8 Reads

Successful treatment of severe aplastic anemia with syngeneic stem cell transplantation in the setting of active disseminated mucormycosis.

Med Mycol Case Rep 2019 Mar 12;23:68-71. Epub 2019 Jan 12.

Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Medical Center, 113-6044 Beirut, Lebanon.

Severe aplastic anemia (SAA) is a hematological disease resulting in pancytopenia due to bone marrow failure. Treatment consists of immunosppressive therapy, or allo-SCT. Patients with aplastic anemia are predisposed to invasive fungal infections due to mucormycosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mmcr.2019.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349008PMC
March 2019
1 Read

Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia.

Haematologica 2019 Feb;104(2):215-216

Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita' Cattolica del Sacro Cuore, Rome, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.207167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355485PMC
February 2019
1 Read

Hematopoietic stem cell transplantation with alpha/beta T-lymphocyte depletion and short course of eculizumab in adolescents and young adults with paroxysmal nocturnal hemoglobinuria.

Ter Arkh 2018 Aug;90(7):57-64

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Department of optimization treatment and prevention of complications of hematopoietic stem cell transplantation, Moscow, Russia.

Aim: The main goal is to optimize hematopoietic stem cell transplantation (HSCT) approach among adolescents and young adults with paroxysmal nocturnal hemoglobinuria (PNH) by means of Graft-versus-host disease (GVHD) and post-transplant complications risk lowering.

Materials And Methods: We report our experience of HSCT from HLA-matched unrelated donors using TCR alfa/beta and CD19 depletion in 5 pts (1M/4F) with PNH, developed after successful immunosuppressive therapy (IST) of acquired aplastic anemia (AA). Median age of pts at the moment of transplantation was 17,8 years (range 14,5-22,7), median interval from IST to PNH was 4 years (5mo - 6,5 y). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/terarkh201890757-64DOI Listing
August 2018
4 Reads

Clonal hematopoiesis: Pre-cancer PLUS.

Adv Cancer Res 2019 14;141:85-128. Epub 2019 Jan 14.

Department of Pathology, Stanford University, Stanford, CA, United States. Electronic address:

Clonal hematopoiesis is a common, age-related process in which a somatically mutated hematopoietic precursor gives rise to a genetically distinct subpopulation in the blood. This phenomenon has been observed in populations across the globe and, while virtually non-existent in children is estimated to affect >10% of the 70-and-older age group. The mutations are thought to occur in stem cells, which makes them pre-cancerous, and precursors to cancer stem cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0065230X183007
Publisher Site
http://dx.doi.org/10.1016/bs.acr.2018.12.003DOI Listing
January 2019
10 Reads

Rare Presentation of Mucormycosis in Aplastic Anaemia: Isolated Hepatic Mucormycosis.

Mycopathologia 2019 Jan 25. Epub 2019 Jan 25.

Department of Internal Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11046-018-0309-yDOI Listing
January 2019
1.528 Impact Factor

Genomic insult oriented mitochondrial instability and proliferative hindrance in the bone marrow of aplastic mice including stem/progenitor population.

Pathol Res Pract 2019 Jan 18. Epub 2019 Jan 18.

Stem Cell Research and Application Unit, Department of Biochemistry and Medical Biotechnology, Calcutta School of Tropical Medicine, 108, C.R Avenue, Kolkata, 700073, West Bengal, India. Electronic address:

Aplastic anemia is the bone marrow failure condition characterized by the development of hypocellularity in both marrow and peripheral blood compartments. Anti-tumor chemotherapeutic agents often exert secondary effect on hematopoietic system leading to aplastic anemia by marrow failure. The precise mechanisms behind the marrow ablative effects of the drugs remain yet to be established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.01.028DOI Listing
January 2019
2 Reads

Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia.

Bone Marrow Transplant 2019 Jan 22. Epub 2019 Jan 22.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.

Our study aimed to compare treatment outcomes between hematopoietic stem cell transplantation (HSCT) from haploidentical donors (HID) and immunosuppressive therapy (IST) in adults with acquired severe aplastic anemia (SAA). The medical records of 113 SAA adults who received IST, including rabbit ATG and cyclosporin (N = 37), or HID HSCT (N = 76) within 6 months of diagnosis at two institutions were retrospectively reviewed. Estimated 8-year overall survival (OS) was comparable between the IST and HID HSCT groups (75. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0410-3DOI Listing
January 2019
2 Reads

Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia.

Bone Marrow Transplant 2019 Jan 22. Epub 2019 Jan 22.

Centre de Référence Aplasie Médullaire, Service d'Hématologie Greffe, Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0452-1DOI Listing
January 2019
1 Read

MDS overlap disorders and diagnostic boundaries.

Blood 2019 Mar 22;133(10):1086-1095. Epub 2019 Jan 22.

Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, CA.

Myelodysplastic syndromes (MDS) are clonal diseases defined by clinical, morphologic, and genetic features often shared by related myeloid disorders. The diagnostic boundaries between these diseases can be arbitrary and not necessarily reflective of underlying disease biology or outcomes. In practice, measures that distinguish MDS from related disorders may be difficult to quantify and can vary as disease progression occurs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-844670DOI Listing
March 2019
2 Reads

Pharmacokinetics study of 16 representative components from Baoyuan Decoction in rat plasma by LC-MS/MS with a large-volume direct injection method.

Phytomedicine 2018 Sep 13;57:148-157. Epub 2018 Sep 13.

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China. Electronic address:

Background: Baoyuan decoction (BYD), a well-known traditional Chinese medicine (TCM) formula, is clinically used for the treatment of aplastic anemia, chronic renal failure, coronary heart disease, etc. PURPOSE: The purpose of this study was to develop a large-volume direct injection liquid chromatography-mass spectrometry (LC-MS) method for simultaneous determination of 16 representative flavonoids and saponins in rat plasma after oral administration of BYD.

Methods: The rat plasma sample was injected directly into a pre-column, which was eluted firstly by 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phymed.2018.09.002DOI Listing
September 2018
1 Read

Sequential liver and haematopoietic stem cell transplantation in a case of fulminant hepatitis associated liver failure and aplastic anaemia.

Eur J Haematol 2019 Apr 15;102(4):375-377. Epub 2019 Feb 15.

Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

The management of severe aplastic anaemia is particularly challenging when it occurs in the context of recent liver transplantation. Rapid identification of a suitable donor followed by allogeneic haematopoietic stem cell transplantation is the only curative option. This scenario is often complicated by potentially life-threatening infections that develop as a consequence of immunosuppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13213DOI Listing
April 2019
4 Reads

Disease modeling of bone marrow failure syndromes using iPSC-derived hematopoietic stem progenitor cells.

Exp Hematol 2019 Mar 19;71:32-42. Epub 2019 Jan 19.

Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan. Electronic address:

The plasticity of induced pluripotent stem cells (iPSCs) with the potential to differentiate into virtually any type of cells and the feasibility of generating hematopoietic stem progenitor cells (HSPCs) from patient-derived iPSCs (iPSC-HSPCs) has many potential applications in hematology. For example, iPSC-HSPCs are being used for leukemogenesis studies and their application in various cell replacement therapies is being evaluated. The use of iPSC-HSPCs can now provide an invaluable resource for the study of diseases associated with the destruction of HSPCs, such as bone marrow failure syndromes (BMFSs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2019.01.006DOI Listing
March 2019
8 Reads

Comparison of Outcomes of Frontline Immunosuppressive Therapy and Frontline Haploidentical Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia Who Lack an HLA-Matched Sibling Donor.

Biol Blood Marrow Transplant 2019 Jan 15. Epub 2019 Jan 15.

Department of Hematology, People's Hospital of Zhengzhou University, Henan, China. Electronic address:

We compared the outcomes of immunosuppressive therapy (IST) with those of T cell-replete haploidentical donor hematopoietic stem cell transplantation (haplo-HSCT) in children and adolescents with severe aplastic anemia (SAA). The medical records of 49 patients with SAA who received frontline IST (n = 29) or frontline haplo-HSCT (n = 20) between 2012 and 2016 were analyzed retrospectively. Fourteen patients responded after the first IST, and 1 patient responded after the second IST in the frontline IST group; 12 patients underwent salvage HSCT after IST failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.017DOI Listing
January 2019
11 Reads
3.404 Impact Factor

A cohort study of immune and hematopoietic functionality changes in severe aplastic anemia patients treated with immunosuppressive therapy.

Medicine (Baltimore) 2019 Jan;98(3):e14149

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.

To investigate if variations in immune and hematopoietic parameters correlated with immunosuppressive therapy (IST) in severe aplastic anemia (SAA) patients.A total of 115 SAA patients who received IST were included. Their immune and hematopoietic functionality changes had been evaluated at 0, 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370062PMC
January 2019
8 Reads

Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer.

Case Rep Hematol 2018 13;2018:9249506. Epub 2018 Dec 13.

Section of Hematology and Medical Oncology, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA.

Breast cancer is the most common cancer diagnosed in women worldwide. Over the years, breast cancer treatment has undergone revolutionary changes especially for women with hormone receptor positive metastatic disease. As a result, women are living longer with their disease, particularly in developed countries. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/crihem/2018/9249506/
Publisher Site
http://dx.doi.org/10.1155/2018/9249506DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311830PMC
December 2018
7 Reads

Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia.

Authors:
George E Georges

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Fred Hutchison Cancer Research Center, Seattle, Washington; University of Washington, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.015DOI Listing
January 2019
1 Read

Comparable Outcome with a Faster Engraftment of Optimized Haploidentical Hematopoietic Stem Cell Transplantation Compared with Transplantations from Other Donor Types in Pediatric Acquired Aplastic Anemia.

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center Children's Hospital, Seoul, Korea.

Haploidentical family donors have been used as an alternative source in hematopoietic cell transplantation for patients with severe aplastic anemia. We evaluated and compared the outcomes of transplantation in pediatric acquired severe aplastic anemia based on donor type. Sixty-seven patients who underwent transplantation between 1998 and 2017 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.010DOI Listing
January 2019
2 Reads

The Progress of Traditional Chinese Medicine in the Treatment of Aplastic Anemia.

J Transl Int Med 2018 Dec 31;6(4):159-164. Epub 2018 Dec 31.

Department of Hematology, First Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China.

Aplastic anemia (AA) is a common hematologic disease that is characterized by hematopoietic failure of the bone marrow and pancytopenia of the peripheral blood, which can be divided into severe and non-severe aplastic ane-mia, or acute and chronic aplastic anemia according to the severity of the disease and the progress of the clinical course. During the past years, the advantages of Traditional Chinese Medicine (TCM) on the treatment of AA have been well clarified and its theory system has been improved as well. This review is mainly on representing the pathogenesis, therapeutic principle and method, research progression, and advantages of TCM on AA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/jtim-2018-0031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326026PMC
December 2018

Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

Cancer Med 2019 Feb 11;8(2):543-553. Epub 2019 Jan 11.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Fatigue is distressing and affects quality of life (QoL) among patients with myelodysplastic syndrome (MDS), aplastic anemia (AA), and paroxysmal nocturnal hemoglobinuria (PNH). Limited data exist on the impact of fatigue, QoL, and related symptoms in these patients.

Objective: Prospectively assess fatigue (functional assessment of cancer therapy-anemia [FACT-An]); QoL (FACT-An subscales); pain (brief pain inventory); and depression, anxiety, and stress (depression anxiety stress scale-21) and strategies used to manage these symptoms in patients with MDS, AA, and PNH. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cam4.1953
Publisher Site
http://dx.doi.org/10.1002/cam4.1953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382725PMC
February 2019
7 Reads

Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients.

Int J Hematol 2019 Mar 9;109(3):278-285. Epub 2019 Jan 9.

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.

We retrospectively analyzed efficacy and safety of therapy with rabbit antithymocyte globulin (rATG) in combination with cyclosporine A (CsA) in 30 Japanese adult patients with acquired aplastic anemia (AA) in the Kyoto Clinical Hematology Study Group. The median observation period was 31 months and the median age of the patients was 54 years. The objective response rates (ORRs) to rATG plus CsA increased over time until 18 months after the start of treatment; the rate of achievement of better than partial response at 18 months was 66. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-018-02583-w
Publisher Site
http://dx.doi.org/10.1007/s12185-018-02583-wDOI Listing
March 2019
7 Reads

Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome.

Health Sci Rep 2018 May 2;1(5):e50. Epub 2018 May 2.

Department of Central Clinical Laboratory Osaka Medical College Hospital Takatsuki Osaka Japan.

Background: Hematologic disorders, including myelodysplastic syndrome (MDS), are difficult to identify in routine hematologic examinations using automated hematology analyzers. However, the practical uses of mean platelet component and mean platelet volume (MPV) measured by these analyzers as screening markers for MDS, remain unclear.

Methods: Mean platelet component and MPV values were measured in the peripheral blood of patients with MDS, aplastic anemia, idiopathic thrombocytopenic purpura, myeloproliferative neoplasms, and in healthy controls using an automated hematologic analyzer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hsr2.50DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266360PMC
May 2018
4 Reads